Wenting Wu, Ph.D., is the primary statistician for the neuro-oncology, chronic lymphocytic leukemia (CLL) and myeloid programs in the Mayo Clinic Cancer Center. Her target in collaboration is to provide high-quality and efficient statistical support for the development of those programs.
Dr. Wu's primary research interest is in the design of clinical trials in oncology. She has been a statistical co-investigator on six R01 grants since 2006 and has more than 40 publications in peer-reviewed journals.
- Personal research. Dr. Wu's personal research includes randomized phase II trials, meta-analyses, surrogate endpoint evaluation, and clinical efficacy endpoint selections in phase II and phase III trials.
- Collaborative research. Dr. Wu collaborates in multiple ongoing clinical trials and clinical and translational research grants in neuro-oncology and CLL programs.
Significance to patient care
Dr. Wu's work in neuro-oncology has identified the most important prognostic factors for recurrent glioblastoma multiforme patients.
Dr. Wu is the primary statistician for the international randomized phase III trial for grade III malignant glioma patients, which is the largest phase III trial in history for this patient population. As the study enrolls patients from the U.S., Mexico, Canada and 300 institutions from Europe, its results will impact and even alter the clinical practice for this population all over the world.
- Director, Biostatistics Core, Mayo Clinic Brain Cancer SPORE, 2011-present